Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menomedin is a multi-component nutraceutical developed by NutriMed Group, specifically formulated to alleviate symptoms associated with menopause and perimenopause. It contains a combination of standardized herbal extracts, including red clover (Trifolium pratense), black cohosh (Cimicifuga racemosa), and sage (Salvia officinalis). These components work synergistically to provide phytoestrogenic activity and modulate neuroendocrine functions, helping to reduce the frequency and intensity of hot flashes, night sweats, and emotional instability. Red clover is rich in isoflavones that mimic estrogen, while black cohosh is traditionally used for its effects on the hypothalamic-pituitary system and neurotransmitter modulation, and sage helps manage excessive sweating. It is marketed as a non-hormonal alternative for managing climacteric syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Menomedin.